2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Qi C, Shen L, Andre T, Chung H, Cannon T, Garralda E, Italiano A, Rieke D, Liu T, Burcoveanu D, Neu N, Mussi C, Xu R, Hong D, Drilon A, Berlin J. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. European Journal Of Cancer 2025, 220: 115338. PMID: 40068370, DOI: 10.1016/j.ejca.2025.115338.Peer-Reviewed Original ResearchTreatment-related adverse eventsSafety of larotrectinibMicrosatellite instability-highGI cancersMedian duration of responseNext-generation sequencing testMedian overall survivalProgression-free survivalDuration of responseNTRK gene fusionsOverall response rateFirst-in-classOverall survivalMedian durationTRK inhibitorsSolid tumorsTumor typesAdverse eventsExtended survivalLarotrectinibGastrointestinal cancerPatientsHepatic cancerResponse rateCancer
2024
Navigating the Complexities of Brain Metastases Management.
Amouzegar A, Haig S, Kahn A, Tawbi H, Jones J, Goldberg S. Navigating the Complexities of Brain Metastases Management. American Society Of Clinical Oncology Educational Book 2024, 44: e433694. PMID: 38781565, DOI: 10.1200/edbk_433694.Peer-Reviewed Original ResearchConceptsBrain metastasesSystemic therapySolid tumorsIncidence of brain metastasesManagement of brain metastasesEfficacy of systemic therapyBrain metastasis managementMetastatic solid tumorsComplication of advanced cancerExclusion of patientsEnhanced imaging technologiesMetastasis managementSystemic treatmentTargeted therapyBreast cancerExtended survivalClinical dataClinical trialsMetastasisAdvanced cancerTherapyEarly detectionTumorPatientsCancerExploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors
Murray M, Noronha K, Wang Y, Friedman A, Paradkar S, Suh H, Sundaram R, Brenner C, Saltzman W, Bindra R. Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors. Molecular Cancer Therapeutics 2024, 23: 1176-1187. PMID: 38691846, PMCID: PMC11292319, DOI: 10.1158/1535-7163.mct-24-0012.Peer-Reviewed Original ResearchConvection-enhanced deliveryCentral nervous systemTreatment of primary central nervous systemPrimary central nervous systemSustained drug release in vitroTumor growth delayAssociated with lower survival ratesBone marrow suppressionComplex mutational profilesNAMPT inhibitorsRelease in vitroIntracranial GBM xenograftsBlood-brain barrierDrug release in vitroRetinal toxicityMarrow suppressionNAMPTiGrowth delayTherapeutic vulnerabilitiesExtended survivalLow survival rateGBM xenograftsMutation profilesPromoter methylationAnticancer activity in vitro
2022
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung CancerPreliminary Activity of Adagrasib in Brain Metastases
Sabari J, Velcheti V, Shimizu K, Strickland M, Heist R, Singh M, Nayyar N, Giobbie-Hurder A, Digumarthy S, Gainor J, Rajan A, Nieblas-Bedolla E, Burns A, Hallin J, Olson P, Christensen J, Kurz S, Brastianos P, Wakimoto H. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung CancerPreliminary Activity of Adagrasib in Brain Metastases. Clinical Cancer Research 2022, 28: 3318-3328. PMID: 35404402, PMCID: PMC9662862, DOI: 10.1158/1078-0432.ccr-22-0383.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerKRAS-mutant non-small cell lung cancerBrain metastasesCerebrospinal fluidAntitumor activityUntreated BMCentral nervous system penetrationDose-dependent pharmacokineticsCell lung cancerKRASG12C inhibitorsPreliminary clinical dataRetrospective database queryCerebrospinal fluid concentrationsPharmacokinetic propertiesExtensive tissue distributionTumor regressionNSCLC xenograftsPreclinical modelsPoor prognosisPreclinical studiesAdagrasibExtended survivalLung cancerClinical dataLong half-life
2019
Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses
Jiang X, Muthusamy V, Fedorova O, Kong Y, Kim DJ, Bosenberg M, Pyle AM, Iwasaki A. Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses. Journal Of Experimental Medicine 2019, 216: 2854-2868. PMID: 31601678, PMCID: PMC6888973, DOI: 10.1084/jem.20190801.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAntineoplastic Agents, ImmunologicalCD8-Positive T-LymphocytesDose-Response Relationship, DrugGene Expression ProfilingImmunologic MemoryInjections, IntralesionalMaleMelanoma, ExperimentalMiceOligoribonucleotidesProgrammed Cell Death 1 ReceptorReceptors, Cell SurfaceTumor BurdenConceptsAntitumor responseNucleic acid-sensing pathwaysSignificant tumor growth delayNumber of CD8Systemic antitumor responseRobust antitumor responseAnti-PD1 antibodyB16 tumor growthImmunogenic tumor modelsCytosolic nucleic acid-sensing pathwaysSingle-agent treatmentTumor growth delayTumor metastasis modelNK cellsMetastasis modelT lymphocytesImmune responseExtended survivalIntratumoral deliveryImmune memoryMyeloid cellsTumor growthGrowth delayTumor microenvironmentTumor modelIntra‐bone bone marrow transplantation from hCD47 transgenic pigs to baboons prolongs chimerism to >60 days and promotes increased porcine lung transplant survival
Watanabe H, Ariyoshi Y, Pomposelli T, Takeuchi K, Ekanayake‐Alper D, Boyd L, Arn S, Sahara H, Shimizu A, Ayares D, Lorber M, Sykes M, Sachs D, Yamada K. Intra‐bone bone marrow transplantation from hCD47 transgenic pigs to baboons prolongs chimerism to >60 days and promotes increased porcine lung transplant survival. Xenotransplantation 2019, 27: e12552. PMID: 31544995, PMCID: PMC7007336, DOI: 10.1111/xen.12552.Peer-Reviewed Original ResearchConceptsLung xenograft survivalAnti-pig antibody levelsPig-to-baboonBone marrow transplantationNegative pigsLung xenograftsMarrow transplantationXenograft survivalPigsPig-to-baboon modelHCD47B cell toleranceLung transplant survivalCellular unresponsivenessAntibody responseLungs 1Antibody levelsGraft survivalProlonged survivalAnimalsT cellsHuman CD47MacrochimerismExtended survivalDays
2018
An atypical case of megacystis microcolon intestinal hypoperistalsis syndrome with extended survival and consistent bowel function
Farrelly J, Weiss R, Copel J, Porto A, Ahle S, Luks V, McGrath J, Stitelman D. An atypical case of megacystis microcolon intestinal hypoperistalsis syndrome with extended survival and consistent bowel function. Journal Of Pediatric Surgery Case Reports 2018, 30: 48-51. DOI: 10.1016/j.epsc.2017.11.010.Peer-Reviewed Case Reports and Technical Notes
2015
Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis
Weiss S, Darvishian F, Tadepalli J, Shapiro R, Golfinos J, Pavlick A, Polsky D, Kirchhoff T, Osman I. Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. BMC Cancer 2015, 15: 926. PMID: 26597176, PMCID: PMC4657192, DOI: 10.1186/s12885-015-1927-0.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesRecurrent brain metastasesBrain metastasesOverall survivalLong-term melanoma survivorsSingle nucleotide polymorphismsYear old manIndividual patient's tumorGenetic variantsMelanoma patientsMelanoma survivorsPrognostic informationFavorable outcomeNRAS wild typePatient outcomesConclusionsOur dataPatient tumorsImmune functionBrain tumorsExtended survivalOlder menPatientsClinical scenariosGermline analysisTherapeutic interventions
2012
Outcomes for Lung Transplantation for Lung Cancer in the United Network for Organ Sharing Registry
Ahmad U, Wang Z, Bryant AS, Kim AW, Kukreja J, Mason DP, Bermudez CA, Detterbeck FC, Boffa DJ. Outcomes for Lung Transplantation for Lung Cancer in the United Network for Organ Sharing Registry. The Annals Of Thoracic Surgery 2012, 94: 935-941. PMID: 22835555, DOI: 10.1016/j.athoracsur.2012.04.069.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Bronchiolo-AlveolarAdultAnalysis of VarianceCause of DeathDisease-Free SurvivalFemaleGraft RejectionGraft SurvivalHospital MortalityHumansImmunohistochemistryKaplan-Meier EstimateLung NeoplasmsLung TransplantationMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPatient SelectionPreoperative CarePrognosisProportional Hazards ModelsRegistriesRetrospective StudiesRisk AssessmentSurvival AnalysisTissue and Organ ProcurementTreatment OutcomeConceptsLung transplantationBronchoalveolar carcinomaLung transplantUnited NetworkLung cancerDouble lung transplantOrgan Sharing databaseOrgan Sharing registrySubgroup of patientsMaximum survival advantageBAC patientsSecond percentExpiratory volumeMedian survivalTransplantation cohortSharing databasePoor prognosisPure adenocarcinomaPathology reportsInvasive tumorsSurvival advantageExtended survivalTransplantationPatientsTransplant
2006
An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens
Wang B, He J, Liu C, Chang L. An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 2006, 24: 3477-3489. PMID: 16530303, PMCID: PMC1850619, DOI: 10.1016/j.vaccine.2006.02.025.Peer-Reviewed Original ResearchConceptsTumor-associated antigensDendritic cellsModification of DCsMultiple tumor-associated antigensStrong anti-tumor responsesReactive dendritic cellsAnti-tumor responseT cell responsesLentiviral vectorsCancer-specific antigensCell antigen 2Tumor-bearing miceThymidine kinase suicide geneDC vaccinesVaccine modalitiesCancer immunotherapyCancer patientsTherapeutic injectionsTherapeutic effectExtended survivalAntigen 2Danger signalsVivo eliminationCell responsesTherapeutic potential
1975
Results of combination chemotherapy of non-Hodgkin's lymphoma.
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Results of combination chemotherapy of non-Hodgkin's lymphoma. British Journal Of Cancer. Supplement 1975, 2: 465-73. PMID: 1101932, PMCID: PMC2149606.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's lymphomaCombination chemotherapyHistological subgroupsLymphocytic lymphomaMonths of treatmentDiffuse histiocytic lymphomaMOPP chemotherapyMedian durationLate recurrenceLymph nodesNodular histologyHistiocytic lymphomaRemissionExtended survivalBone marrowClinical validityLymphomaAdvanced stageChemotherapyPatientsRelapseInitial siteMonthsSurvival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply